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structural equation models (ESEM), a method that can be considered a strong 
alternative to the exclusive use of exploratory factor analysis (EFA) and confirma-
tory factor analysis (CFA) in patient related outcomes measurement. By combining 
the steps of EFA and CFA in one unified approach, ESEM saves significant time 
and effort usually invested in separate iterations of EFA and CFA. Methods: 
One hundred replications of ESEM models were carried out for variations of sam-
ple size and latent factors. Simulation study 1 examined the behavior of ESEM 
parameter estimates by changing the values of rotation constant (0.01, 0.001 and 
0.0001) in Geomin rotation for a three-factor single group model and for N= 300 and 
1000. Simulation study 2 evaluated the behavior of ESEM parameter estimates for 
multi-group models using three- and four-factor models for N= 150 and 500 per 
group. Bias, Mean Square Errors (MSE) and standard errors were used to evaluate 
accuracy of parameter recovery. Item parameters were generated from 27 items 
belonging to a pilot graduate creativity instrument. Results: For study 1, Geomin 
rotated parameter estimates of factor loadings, means and covariances produce 
higher MSEs than the follow up Target rotations. In study 2, the parameter esti-
mates for ESEM Geomin show small sample size bias for some parameters while 
the standard errors produced correct coverage for all parameters under Target 
rotation method for large N= 500 per group. ConClusions: Overall, there was 
accurate recovery of parameter estimates in the smallest sample of 300 especially 
in the multi-group models specifically when Geomin rotations were employed. 
This bodes well for analysis of real data and for the study of measurement invari-
ance across groups. Future studies could include the examination of number of 
items affecting recovery of parameter estimates.
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objeCtives: Historically, cardiovascular (CV) endpoints, including myocardial 
infarction and stroke, have often been included indirectly in cost-effectiveness 
analyses (CEA) based on surrogate endpoints from clinical trials, such as cho-
lesterol levels, blood pressure or glycemic control. With the availability of out-
comes trials sufficiently powered to show differences in CV endpoints, there 
is an increasing need to incorporate these data directly into CEA. This study 
investigated approaches available in the published literature for modeling CV 
endpoints directly based on outcomes data. Methods: A systematic review of 
cost-effectiveness models for cardiovascular interventions published in the past 
5 years was conducted in PubMed and Embase using a predefined search strategy. 
Only studies in English language directly integrating trial data on CV endpoints 
from randomized clinical trials were considered. For each study that met the 
inclusion criteria, clinical input characteristics and the modeling approach were 
summarized and evaluated. Results: Twenty-three papers were identified for 
final review, including studies of antithrombotic, heart failure, and lipid lowering 
therapies. Methodologically, decision trees, Markov models (cohort and individual 
patient), discrete event simulations as well as hybrids of these approaches were 
used. Event rates were incorporated either as constant rates, time-dependent 
risks, or risk equations based on patient characteristics. Although potentially more 
accurately reflecting the trial data, risks dependent on time and/or patient charac-
teristics were only used where feasible (major event rates > 1%/year) and practical 
(models with fewer than seven health states). Models incorporating data from 
infrequent events or with numerous health states generally preferred constant 
event rates. ConClusions: When the risk of CV events is low and/or the disease 
state is explicitly modeled in detail, constant events rates were most common. 
For heterogeneous populations or when CV event risk is high, simpler model 
structures were generally accompanied by patient- or time-dependent event rates 
where permitted by the available data.
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objeCtives: Correlated parameters are a common feature in economic 
models, but no standard sensitivity analysis (SA) exists to show their impact on 
cost-effectiveness. The one-way SA only varies one parameter at a time and ignores 
correlation while the probabilistic SA is typically used to address overall uncertainty. 
The objective of this study is to propose a standard method for visualising the 
impact of one variable consisting of two correlated parameters in cost-effectiveness 
analysis. Methods: A model evaluating the cost-effectiveness of a cancer product 
was used. Using the Cholesky decomposition, 1,000 correlated random draws were 
generated from the distributions of the intercept and slope of a linear function 
determining survival in the model. Each pair was inputted in the model to yield the 
percentage of simulations below accepted thresholds. Results were visualised using 
R in a scatter plot with both parameters on a separate axis. Shaded areas repre-
sented the percentage of simulations below accepted cost-effectiveness thresholds 
and an ellipse was added representing 80% of the simulated parameter combina-
tions. A conventional one-way SA was performed for comparison. Results: The 
one way SA found wide ranges of incremental cost-effectiveness ratios (ICER) for 
the intercept and slope parameters (£10,000 - £50,000 per QALY gained). The method 
described above found that 78% of the simulated pairs resulted in ICERs below 
£20,000 per QALY gained, and 93% in ICERs below £30,000. The scatter plot visualised 
the combined uncertainty and their impact on the ICER. A limitation is that the 
visualisation only allows for 2 correlated parameters. Also, the use of R to generate 
the graph complicates incorporation of this SA in Excel models. ConClusions: 
A method was demonstrated to show the impact of correlated parameters in cost-
effectiveness analyses. This method may be especially helpful when assessing the 
uncertainty around parametric survival fits.
blood pressure 134.9mmHg (22.0) and total cholesterol of 189.8 mg/dl (48.7). The 
expected five-year cumulative MACE event rate was 9.2% and HbA1c reductions 
of 0.5%, 1.0% and 1.5% produced relative risk reductions of 7.5%, 9.0% and 10.6% 
respectively. At the 5% level, the number of patients required to detect a signifi-
cant reduction in MACE events was 17,786, 11,758 and 1,912 for HbA1c reductions 
of 0.5%, 1.0% and 1.5% respectively. On average, each half-unit change in HbA1c 
required an additional 7,937 subjects to detect a significant difference in MACE 
event rate. ConClusions: Given the requirement to extensively validate health 
economic models to contemporary outcomes studies it is an obvious extension 
to use these models to inform on the design of clinical trials. These models offer 
considerable flexibility in the evaluation of sample size requirements in terms of 
expected changes in modifiable risk factors.
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objeCtives: Clinical studies indicate switching to a second biologic or combination 
therapy with an immunosuppressant after failure of first biologic can be effective 
in patients with moderate to severe plaque psoriasis not responding to the first bio-
logic. Methods: A systematic literature review was performed to assess treatment 
pathways included in cost-effectiveness (CE) estimates of biologic treatments of mod-
erate to severe psoriasis and compare these pathways with those recommended 
in psoriasis treatment guidelines. Results: Twenty-one CE modeling studies were 
identified. Of these 10 estimated incremental cost per responder for > = 1 biologics 
over time horizons varying from 12 weeks to 18 months. Treatment pathways were 
considered not relevant in these studies. In 11 studies with time horizons up to 10 
years where treatment pathways were considered, 5 studies included a switch to non-
systemic therapy or best supportive care after failure of the initial biologic. In 6 of 11 
studies, failure of the initial biologic was followed by monotherapy with a second-line 
biologic - one of the recommendations in current treatment guidelines. In only 1 of 
6 studies that considered treatment sequencing was the efficacy of the second-line 
biologic adjusted downwards compared to first line treatment. None of the cost-
effectiveness analyses included dose titration with the first-line biologic or combina-
tion therapy with a biologic plus methotrexate or phototherapy after failure of the 
first-line biologic as recommended in some treatment guidelines. ConClusions: 
In most long term CE studies, failure of the first biologic was followed by biologic 
monotherapy of the second, without efficacy adjustment. Some treatment guidelines 
support dose titration or combination treatment after failure of a first-line biologic. 
Nevertheless, these options were not included in the published CE models with time 
horizons up to 10 years. For decision makers there may be a need for more extensive 
models where such strategies are allowed.
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objeCtives: Drug-eluting stents (DES) and bare-metal stents (BMS) are both used 
widely in percutaneous coronary interventions. However, cost-effectiveness analy-
ses of DES versus BMS conflict about whether the reduction in repeat revascu-
larizations of DES versus BMS offsets the initial higher treatment costs of DES. A 
systematic review was performed to examine whether modelling methods influ-
enced the cost-effectiveness of DES versus BMS. Methods: We reviewed modelling 
studies published until January 2012 that compared the costs and consequences 
of DES versus BMS. General information (e.g. funding) and modelling methods 
used, related to the framing of the economic evaluation (e.g. population and inter-
vention characteristics, time horizon) and parameterisation of the models were 
extracted from the relevant studies for each of the individual analyses performed 
in the studies. Associations between these characteristics and the incremental 
costs and effectiveness were explored using regression analysis. We also exam-
ined whether the results were associated with the quality of the models based on 
the Philips et al. (2006) checklist. Results: Fifteen eligible studies accounted for 
498 separate analyses, in which the incremental cost-effectiveness ratios ranged 
from DES being dominated by BMS to DES being dominant. The most important 
predictors significantly associated with these differences were several population 
and procedure characteristics, funding and assumptions concerning stent efficacy. 
The results and conclusions of individual studies corresponded with the findings 
of this meta-level systematic review. Overall quality of the models was moderate 
(55%±17%) and significantly negatively associated with repeat revascularizations 
avoided. ConClusions: Models are important to obtain valid estimates of the 
cost-effectiveness of DES versus BMS, and framing decisions (e.g. time horizon) 
and quality of the models both influence incremental costs and effects. The most 
influential parameters are identified with this systematic review and we showed 
the need of examining those parameters and of performing a quality check when 
interpreting the results.
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objeCtives: This simulation study evaluates the impact of Geomin and Target 
rotation criteria on factor loading matrices in the recently developed exploratory 
